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 INTRODUCTION:  
Minimally invasive esophagectomy (MIE) is a surgical technique aimed at 
reducing the morbidity of esophagectomy while maintaining oncological adequacy 
and long-term survival.1 An exploratory randomized trial comparing MIE with open 
transthoracic esophagectomy has shown improved short term outcomes and no 
compromise to the quality of surgical resection.2 This trial was small, however, and 
not powered to examine survival or patient-centered outcomes. We have previously 
reported our experience with thoracoscopically-assisted McKeown esophagectomy 
(TAMK), demonstrating that it can be performed safely, with equivalent survival and 
patterns of recurrence when compared with open resection.3,4 We have also reported 
on long term quality of life assessment in a small number of these patients.4 Where 
clinical results and survival data are equivocal patient reported outcomes can offer 
insight into what might be the optimal approach. Health-related quality of life 
(HRQL) is an important outcome measure in surgical oncology as it covers a broader 
aspect of health.5 The patients themselves complete the questionnaires so this data is 
relevant to the everyday life of the patient. Prospective studies assessing the impact 
of esophagectomy on HRQL consistently report that patients experience a general 
decrease in performance and severe fatigue lasting at least six months after surgery,5,6 
and some symptoms will persist in long-term survivors. 4,7 To date, five direct 
comparison studies between MIE and open esophagectomy with HRQL as a primary 
endpoint have been performed. 8-12 However, these are small studies with the longest 
follow up being 12 months post operatively. Long-term outcome data and 
information about long-term HRQL outcomes post minimally invasive 
esophagectomy are lacking. The present study was undertaken to examine and 
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compare self-reported HRQL scores for patients undergoing TAMK (with an open 
abdominal approach) with open transthoracic esophagectomy (Ivor Lewis operation) 
TTIL for esophageal or GEJ cancer using a validated HRQL instrument. 
 
METHODS: 
Health-related quality of life assessment 
Patients who consented to participate in HRQL analysis and who were able to 
speak and read English completed HRQL questionnaires before surgery (baseline, 
within 4 weeks of surgery), at 3 monthly intervals for the first 12 months following 
surgery, 6 monthly intervals to 24 months and annually thereafter to 5 years or until 
death or patient withdrawal from the study. The baseline data were collected within 
clinics in the hospital and subsequent questionnaires were mailed to patients unless 
additional help was required. Questionnaires were completed by the patients. If 
patients did not respond to questionnaires within 4 weeks another questionnaire was 
sent and an attempt was made to contact the patient by telephone from a research 
nurse. Questionnaires were checked for missing answers and if answers were absent, 
patients were contacted and asked to respond to the unanswered questions. HRQL 
items that remained unanswered were handled using imputation as recommended by 
the developers.13 Patients with missing forms were excluded from analysis of the 
absent assessment points.  
 The instrument used was the European Organisation for Research and 
Treatment of Cancer (EORTC) QLQ-C30 (version 3.0) and Oesophageal Cancer 
Module QLQ-OES18. 13-17 The EORTC QLQ-C30 contains scales and items 
addressing functional aspects of HRQL and symptoms that commonly occur in 
cancer, as well as items assessing the financial impact of malignant disease and 
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global HRQL. The QLQ-OES18 module focuses on symptoms specific to 
oesophageal cancer treated with single or multimodal treatment. Both questionnaires 
have been validated.14 All QLQ-C30 and QLQ-OES18 responses were linearly 
transformed to scores from 0 to 100.16 For functional and global health status scales, 
a higher score represents a high/healthy level of functioning, whereas for a symptom 
scale or single item, a high score represents a high level of symptom/problem.16 
Mean scores were calculated at baseline and at each assessment point to 24 months 
for both groups of patients.  
We collected information in a prospectively maintained esophagogastric 
cancer database. We identified 487 consecutive patients with esophageal or GEJ 
cancer selected for TAMK (with thoracoscopic mobilization) or TTIL (with an open 
thoracotomy) who had completed pre-treatment (baseline) HRQL questionnaires 
(Fig. 1) at the Princess Alexandra Hospital between 1998 and 2011. Permission to 
collect and use the information in the database was approved by the hospital ethics 
committee.  
Tumour staging and Siewert classification was performed with endoscopy, 
computerized tomography of chest and abdomen and staging laparoscopy. Positron 
emission tomography (PET) scans were routinely performed from 2004. Endoscopic 
ultrasound, as it became available was used selectively for staging. Treatment 
decisions were all made at an upper gastrointestinal multi-disciplinary team meeting 
with surgery alone used as a result of randomization within clinical trials, 18 inability 
to receive neoadjuvant treatment or patient preference.  
Surgery  
All operations were performed with curative intent. The operative techniques 
have been described in detail previously.1, 3, 4 TTIL was defined as resection of the 
 7 
proximal stomach and thoracic esophagus via laparotomy for gastric mobilisation 
and right transthoracic esophagectomy with esophagogastric anastomosis in the chest 
(Ivor Lewis operation).19 TAMK was thoracoscopically-assisted mobilization of the 
thoracic esophagus with a laparotomy approach to allow resection of the proximal 
stomach and construction of the gastric tube for an esophagogastric anastomosis in 
the neck.1 The selection criteria for TTIL or TAMK were solely related to the site of 
the cancer and the degree of gastric resection required to achieve appropriate 
resection margins which would allow (or not allow) a gastric tube reconstruction to 
be taken to the neck for anastomosis. If there was more than 2cm of gastric cardia 
involved the Ivor Lewis approach (TTIL) was performed via thoracotomy solely to 
facilitate the anastomosis. Procedure-related mortality was defined as death in 
hospital and/or death within 90 days of operation. 
Follow-up 
Patients were followed clinically every 3 months for the first two years, six 
monthly for two years and annually to 10 years. Patients underwent cross sectional 
imaging and endoscopy when symptoms or signs were suspicious for recurrent 
disease.  
Data Analyses 
 Statistical analysis was carried out with SPSS for Windows, version 
17.0 (Statistical Package for the Social Sciences, SPSS, Inc., Chicago, IL), SAS, 
version for Windows 9.1 (SAS Institute, Cary, NC) and R (version 3.2.3). 
Continuous variables were expressed as median (minimum-maximum) and compared 
using the Mann Whitney test, whereas categorical variables were compared using the 
χ2 or Fisher's exact test. Unadjusted differences in survival for categorical or 
continuous clinicopathological variables were compared via the Log Rank test or 
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Cox regression analyses, respectively. Overall survival probabilities were estimated 
by the Kaplan-Meier method, with differences in survival rates assessed using the 
log-rank test to determine univariable significance. Multivariable analysis was 
performed using forward stepwise Cox regression (entry criterion Wald) test, 
including post-operative AJCC stage, age, histological subtype, comorbidity and type 
of operation.  
 The difference from baseline was calculated for each HRQL parameter. A 
difference of ≥5 points was considered a significant change in HRQL, as has been 
previously reported.11, 20, 21, 22 To allow for correlation of outcomes within 
individuals, generalised estimating equations (GEE) were employed. 23,24 Differences 
over time in mean HRQL scores between TAMK and TTIL adjusted for covariates 
selected a priori as potential modifiers of HRQoL including gender, age, 
histopathology, stage, neoadjuvant treatment and type of surgery were estimated and 
tested using GEE.  
 Additionally, in a separate analysis, GEE were employed with propensity 
score adjustment.25,26 Propensity scores were calculated using the gbm package 
(version 2.1.1)27 in R (version 3.2.3)28.The propensity scores were estimated by 
boosted regression of treatment (TAMK versus TTIL) on age, gender, histological 
type, neoadjuvant therapy, tumor site, clinical stage, American Society of 
Anesthesiologists (ASA) classification, and the presence of comorbidity (yes/no). 
Boosted regression was used to account for possible interactions between the 
included covariates. The distribution of boosted regression propensity scores between 
the TAMK and TTIL groups are shown in Supplementary Figure 1. They were then 
applied using the third method of Kurth et al (2006)29 where GEE were adjusted 
using the propensity scores as a linear term. Following the recommendations of 
 9 
Kurth et al, the inverse weighting methods were not employed since the weights of 
several individuals were very large. Note that, as expected, when adjusted for 
propensity scores, the pre-treatment covariates were not significantly different 
between surgery groups. In addition to the propensity scores, the GEE also included 
type of surgery and post-operative pathological stage, which were chosen a priori as 
potential modifiers of HRQoL. Results of GEE using boosted propensity score 
analysis are presented here since in most cases they were nearly identical to the 
results obtained from GEE adjusted for covariates (including gender, age, 
histopathology, stage, neoadjuvant treatment and type of surgery). 
In addition, propensity scores were computed by logistic regression using the 
nonrandom package (version 1.42) 30 (data not shown). Analogous to our boosted 
regression model, treatment (TAMK versus TTIL) was regressed on age, gender, 
histological type, neoadjuvant therapy, tumor site, clinical stage, American Society 
of Anesthesiologists (ASA) classification, and the presence of comorbidity (yes/no). 
Adjustment of GEEs with propensity scores computed by boosted regression and 
logistic regression yielded highly similar results (data not shown). 
Unless otherwise stated, a significance level of 0.05 was used for all statistical 
tests. 
RESULTS: 
Clinicopathological variables and survival  
 Of the 487 patients, 377 underwent TAMK and 110 underwent TTIL (Table 
1). The majority of the patients were male in both treatment groups. Age, ASA grade, 
and exposure to preoperative treatment were similar between groups. Average tumor 
length and R0 resection status were also similar between groups, but patients 
undergoing TTIL were significantly more likely to have an adenocarcinoma, tumor 
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involving the GEJ, and a more advanced tumor stage at resection (Table 1). Length 
of hospital stay was shorter in the TAMK group 13 days (8-123) compared to 15 
days (8-56) in the TTIL group (Mann-Whitney, p<0.01). Due to the long period of 
the study, we analysed the patterns of care by 5-year time periods: 1998-2002; 2002-
2007; and 2007-2011 (Supplementary table 1). Over the time period of the study, the 
only significant difference in treatment-related variable was an increase in the use of 
neoadjuvant therapy over time (p<0.001). 
 The median overall survival was 53 months (range 2-151) for TAMK 
compared with 24 months (range 5-135) for the TTIL group (Log rank, p<0.01, 
Supplementary Figure 2). However, operative approach was not associated with 
overall survival in a multivariable model adjusting for post-operative AJCC stage, 
age, histological subtype, comorbidity and type of operation (Supplementary Table 
2). 
Questionnaire compliance and missing data 
At the end of 2 years there were 60 patients (12%) with missing HRQL data 
and 153 patients (35%) had died. Attrition rates due to disease progression were high 
for both groups with 271 (72%) TAMK patients and 63 (57%) TTIL patients alive at 
2 years (Table 2). Compliance during follow-up was generally very high with >99% 
at 3 and 6 months, >95% at 12 months and >85% at 24 months, Table 2. Clinical and 
sociodemographic data were similar in patients with and without baseline HRQL data 
and there were no differences in the completion rates between the two treatment 
groups.  
Health-related quality of life functional outcomes 
Patients selected for TAMK or TTIL reported similar baseline HRQL scores 
for all functional scales (Table 3 and 4, Student’s t-test). Physical, role, and social 
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function deteriorated by over 15 points after TAMK and TTIL (Table 3). Mean 
physical and social function scores “recovered” to within 10 points of baseline at 12 
months for the TAMK group but not the TTIL group (Supplementary Fig. 3). Mean 
role function scores “recovered” to within 10 points of baseline at 24 months for the 
TAMK group but did not for the TTIL group. Emotional function was low in both 
groups at baseline, decreased further at 3 months, but then steadily improved after 
surgery in both groups to overall higher scores at 12 months than at baseline 
(Supplementary Fig. 4). Similarly global quality of life scores were low at baseline, 
decreased at 3 months but thereafter improved with higher overall scores at 24 
months in both groups (Supplementary Fig. 5).  
 Longitudinal analyses were undertaken comparing TAMK and TTIL using 
GEE with propensity score adjustment (propensity scores are shown in 
Supplementary Figure 1). There were no significant differences between the TAMK 
and TTIL groups over time for any of the functional scales, although there was trend 
towards better physical function scores for TAMK.  
These analyses were repeated for 313 patients (255 TAMK and 58 TTIL) who 
had no evidence of recurrence for at least 27 months after surgery to minimize the 
impact of disease recurrence on HRQoL (Supplementary Table 3). For these long 
term survivors, physical function and global HRQoL score demonstrated trends 
towards more favorable scores for TAMK compared with TTIL groups over time, but 
were not statistically significant. 
Health-related quality of life symptom outcomes: single-item scales 
Patients selected for TAMK or TTIL reported similar baseline scores for all 
single-item scales (Table 4, p=not significant, Student’s t-test). Self-reported mean 
scores for the single-items reflux, speech problems, odynophagia, insomnia, 
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swallowing problems and dry mouth did not change by more than 10 points for either 
TAMK or TTIL at any time after surgery, although after 6 months the TAMK group 
reported scores >5 points lower for odynophagia than the TTIL group. Dysphagia 
scores did not show a significant decline until 6 months after surgery for the TTIL 
group and 12 months after surgery for the TAMK group, respectively. Mean 
constipation scores did not change after TAMK, but showed a decline of 15 points 
for the TTIL group, that “recovered” at 6 months after surgery. All other mean single 
item scales deteriorated by over 10 points in the 3 months after TAMK and TTIL 
(Table 4). Mean pain and nausea and vomiting “recovered” to within 10 points of 
baseline at 6 months for the TAMK group and 12 months for the TTIL group. 
Insomnia recovered after 6 months for both groups. For the TAMK group, anorexia, 
eating problems, and taste recovered after 12 months; fatigue and dyspnea recovered 
after 24 months. Cough and diarrhea scores failed to “recover” within 24 months for 
the TAMK group. For the TTIL group, anorexia and eating problems recovered after 
6 months; taste and dyspnoea recovered after 12 months. Cough and fatigue scores 
failed to recover within 24 months following TTIL. 
Longitudinal analyses were also undertaken comparing TAMK and TTIL using 
GEE with propensity score adjustment. Mean symptom scores for pain were 
significantly higher (worse) in the TTIL group compared with TAMK at every time 
point for two years post-operatively (Supplementary Fig.6, p=0.036). Mean scores 
for odynophagia were significantly worse in the TTIL group (p=0.04), although 
changes from baseline mean scores were <5 in each group at all time points. In 
addition, mean constipation scores were significantly higher (worse) for the TTIL 
group, with a 15 point difference in mean score at 3 months post operatively 
(Supplementary Fig 7, p=0.037).  
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These analyses were repeated for 313 patients (255 TAMK and 58 TTIL) who 
had no evidence of recurrence for at least 27 months after surgery (Supplementary 
Table 4). For these long term survivors, mean symptom scores for pain, 
odynophagia, and constipation were >5 points higher (worse) in the TTIL group 
compared with TAMK 6 months to two years post-operatively but did not reach 
statistical significance. 
DISCUSSION: 
 To further supplement decision-making, this study examined the impact of 
TTIL and TAMK on self-reported health-related quality of life in a prospective non-
randomized cohort of patients. After adjusting for known confounding factors it was 
observed that patients undergoing TAMK reported fewer HRQL problems, 
significantly less pain, constipation, in the first 24 months after surgery than patients 
selected for TTIL. This is an important finding and further work is needed to 
establish whether TAMK confers this observed patient benefit in the longer term. 
 Several studies have compared HRQL in MIE to open surgery but there are a 
lack of prospective studies with comprehensive HRQL assessments and long term 
follow up.2, 7, 31 There is also a lack of comparative randomized and non-randomized 
data in this setting. 4, 32 Three small non-randomized comparison studies between 
MIE and open surgery are published. 8,9,11 To date, there are only two randomized 
studies, one assessing 114 patients (59 open esophagectomy versus 59 MIE) but the 
authors only followed up patients for 12 weeks post operatively,10 and one assessing 
64 patients (31 open versus 33 MIE) with 1 year follow up.12 The studies used the 
EORTC generic and disease specific measures, QLQ-C30 and QLQ-OES18 to assess 
HRQL and they both reported a significant decline in physical function, global 
quality of life (QoL) and pain with faster recovery in the MIE group.10, 12 In the 
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current study similar early reduction in physical, role, and social function was 
observed in both groups post operatively, but there was faster recovery in the TAMK 
group. These results were also observed for the subset of long term survivors who 
showed now evidence of disease recurrence for at least 27 months after surgery. All 
studies showed early differences between the groups in physical functioning 
recovery. Zeng et al analyzed HRQL data in open versus MIE up to 24 weeks post 
operatively and found a significant early decrease in social function in the open 
group. Wang et al reported a non-randomized comparison of 27 patients selected for 
thoracoscopic mobilization with 29 selected for standard open esophagectomy and 
found global health scores to be significantly better in the minimal access group. 9 
Parameswaran et al reported a two centre non-randomized study of open and 
minimally invasive approaches to esophagectomy. It was found that all patients had 
decreased ability to perform activities of daily living after all types of surgical 
approaches but more rapid improvements were observed after MIE. 11 This study, 
however, did not adjust for baseline differences in the highly selected patients. In the 
largest study (which was randomized) assessing 114 patients, significant declines in 
physical and global quality of life (QoL) with faster recovery in the MIE group were 
found. 10 We demonstrated a slight decrease in emotional and global QoL scores post 
operatively but an actual improvement thereafter, with scores being higher than 
baseline at 2 years.  
Some studies report significant functional symptoms such as reflux or dumping 
following esophagectomy but preserved QoL with the explanation that despite even 
potentially debilitating symptoms, QoL is preserved because patients are happy to be 
alive and disease-free.33 With regard to symptom scores, most mean single item 
scales deteriorated by over 10 points in the 3 months after TAMK and TTIL with 
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pain nausea and vomiting “recovering” to within 10 points of baseline at 6 months 
for the TAMK group and 12 months for the TTIL group. This is consistent with 
previous studies consistently showing a more rapid return to baseline for MIE. 8-11 
Other comparison studies have shown significant reflux postoperatively in both MIE 
and open, which we did not find, this may be related to anastomotic technique. 8,9 
Having performed longitudinal analyses using GEE mean symptom scores for pain 
were significantly higher in the TTIL group compared with TAMK for two years 
post-operatively, although for the subset of long term survivors the observed >5 point 
differences did not reach statistical significance. In addition, mean constipation 
scores were significantly higher for the TTIL group. We feel that these outcomes are 
related, increased ingestion of opiate analgesia resulting in constipation. Three other 
comparison studies have shown an association with MIE and decreased pain scores. 8-
10 However, they only followed patients for 24 weeks postoperatively and cannot 
comment on whether patients do return to baseline after this time period. 
 Our study is a comprehensive analysis of longitudinal HRQL (from baseline 
to >2 years post operatively) in a large cohort (487 patients), including subset 
analyses of long term survivors. The high compliance rate and the use of a validated 
multi-dimensional questionnaire minimizes both selection and information bias. The 
prospective and longitudinal design also strengthens the study. Limitations to this 
study include the fact that it is a non-randomized comparison study and therefore 
observed differences in HRQL may reflect other clinical variables that were not 
adjusted for. Moreover, all patients were treated by a single, high volume surgical 
unit potentially limiting the generalizability of the findings. There were more patients 
with SCC in the TAMK group, while there were more stage III patients in the TTIL 
group. These differences are the result of our policy of minimal gastric involvement 
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to allow cervical anastomosis (with SCC and smaller tumours less likely to involve 
>2cm of gastric cardia), rather than deliberate selection of earlier tumours for 
TAMK. SCC histology and stage III and IV disease have been associated with worse 
HRQL scores 6 months after surgery in a large population-based HRQL study from 
Sweden.34 We adjusted for these and other factors known to be associated with 
HRQL (neoadjuvant treatment, age and gender) in our final analysis using propensity 
score adjustment as well as repeating the analyses for the subset of long term 
survivors and HRQL parameters remained better for the TAMK group.  
 For esophageal cancer, where several surgical options are available including 
open, hybrid MIE and total MIE, HRQL scores can help to guide therapy by allowing 
patients and clinicians to make more informed treatment decisions. This prospective 
study provides data to support the view that TAMK is a reasonable surgical choice 
because it has a less, albeit modest, deleterious impact on HRQL. Given that the 
observed differences were largely related to pain, our data suggest that thoracoscopy, 
rather than anastomotic site, has some HRQoL-related benefits over thoracotomy. 
This study highlights the need for further comparative HRQL studies with 
prospective, long term follow up from multiple surgical units to determine the 
applicability of the results in the broader context. In particular, studies of 
thoracoscopically-assisted esophagectomy comparing anastomotic site in the neck 
with the chest (Ivor Lewis) are areas for further research. Such studies would support 
the need for a randomized clinical trial designed to address HRQL outcomes over the 
short, medium and long term to confirm the benefits we have found.  
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Figure Legend 
Figure 1:  
Consort Diagram for study. MIE=Minimally Invasive Esophagectomy. 
HRQL=Health Related Quality of Life. 
 
Supplementary Figure 1:  
Mirrored histogram of propensity scores by relative frequency for both groups. 
TAMK=Thoracoscopically Assisted McKeown esophagectomy, TTIL=Transthoracic 
Ivor Lewis esophagectomy. 
 
Supplementary Figure 2:  
Kaplan Meier Survival Curve and Table for both groups. TAMK=Thoracoscopically 
Assisted McKeown esophagectomy, TTIL=Transthoracic Ivor Lewis 
esophagectomy.  
 
Supplementary Figure 3  
Graph of mean physical function scores over time for both groups, adjusted for 
propensity scores. TAMK=Thoracoscopically Assisted McKeown esophagectomy, 
TTIL=Transthoracic Ivor Lewis esophagectomy.  
 
Supplementary Figure 4  
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Graph of mean emotional function scores over time for both groups, adjusted for 
propensity scores. TAMK=Thoracoscopically Assisted McKeown esophagectomy, 
TTIL=Transthoracic Ivor Lewis esophagectomy.. SE=Standard Error. 
 
Supplementary Figure 5  
Graph of mean global Quality of Life scores over time for both groups, adjusted for 
propensity scores. TAMK=Thoracoscopically Assisted McKeown esophagectomy, 
TTIL=Transthoracic Ivor Lewis esophagectomy. SE=Standard Error. 
 
Supplementary Figure 6 
Graph of mean pain scores over time for both groups, adjusted for propensity scores. 
TAMK=Thoracoscopically Assisted McKeown esophagectomy, TTIL=Transthoracic 
Ivor Lewis esophagectomy. SE=Standard Error. 
 
Supplementary Figure 7  
Graph of mean constipation scores over time for both groups, adjusted for propensity 
scores. TAMK=Thoracoscopically Assisted McKeown esophagectomy, 
TTIL=Transthoracic Ivor Lewis esophagectomy.. SE=Standard Error. 
 
